News

Sanofi ramps up artemisinin plant
Enlarge image

BusinessItalyFranceBulgaria

Sanofi ramps up artemisinin plant

12.04.2013 - From its Italian manufacturing site at Garessio, Sanofi has launched large-scale production of semi-synthetic artemisinin, a potent anti-malarial drug.

The launch of the new facility on April 11 represents a further milestone in an anti-malarial drug partnership led by OneWorld Health, a non-profit drug development organisation, with funding from the Bill & Melinda Gates Foundation. Sanofi has invested €10m to build an industrial-scale plant that converts the biological precursor artemisinic acid into artemisinin in reaction steps that involve photochemistry. With its photochemical batch-flow-reactor technology in action, Sanofi envisions a production of 35 tonnes of semi-synthetic artemisinin in 2013, with the first batches available by this summer. It plans to increase capacity to 60 tonnes per year in 2014 and thereafter, which would meet at least a third of the annual global need for the drug. Sanofi hopes to get WHO approval for its product in the coming weeks.

From a technology perspective, the semi-synthetic artemisinin project is a combination of biotechnological and chemical know-how at the industrial scale. Artemisinin is a secondary metabolite extracted from the traditional Chinese medical herb Artemisia annua. However, the botanical supply is subject to climatic variables, leading to a fluctuation in antimalarial medicines and big price variations. Aiming for a stable and more reliable supply of the drug, Jay Keasling and his team at the University of California Berkeley and synthetic biology start-up Amyris genetically engineered yeast cells to produce the precursor artemisinic acid, which must then be converted into artemisinin by synthetic organic chemistry. Sanofi entered the project in 2008 as manufacturing partner with its Access to Medicines programme, and was involved in scaling-up fermentation of artemisinic acid and its conversion into artemisinin using photochemistry. At a facility run by Huverpharma in Bulgaria, an industrial-scale fermentation process was established that could produce up to 100 tonnes of artemisinic acid annually. It is considered as the first industrial-scale deployment of synthetic biology for drug production. Sanofi said it will provide its semi-synthetic artemisinin at a stable price using a non-profit, non-loss production model.

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/sanofi-ramps-up-artemisinin-plant.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF21.8%
  • MAGFORCE6.90 EUR10.8%
  • BB BIOTECH140.45 EUR5.1%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.85 EUR-19.5%
  • VITA 343.75 EUR-17.6%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR188.4%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-68.1%
  • MERCK KGAA66.20 EUR-43.4%

No liability assumed, Date: 26.08.2014